Responder characteristics to a single oral dose of cholinesterase inhibitor: A double-blind placebo-controlled study with tacrine in Alzheimer patients

Dementia and Geriatric Cognitive Disorders

Volumn 12, Issue 1, 2001, Pages 22-32

  Almkvist, O ^a   Jelic, V ^a   Amberla, K ^a   Hellstrom Lindahl E ^a   Meurling, L ^a   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease, acetylcholinesterase activity; Cholinesterase inhibitor; Responders; Single dose; Tacrine

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; TACRINE;

ADULT; AGED; ALPHA RHYTHM; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ELECTROENCEPHALOGRAM; FEMALE; GENE FREQUENCY; GLUCOSE METABOLISM; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; PRIORITY JOURNAL; TEMPORAL CORTEX; THETA RHYTHM; TREATMENT OUTCOME;

ACETYLCHOLINE; ADMINISTRATION, ORAL; AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATTENTION; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TACRINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035189162     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051232     Document Type: Article

References (75)

1. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology
2. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
3. Tacrine in Alzheimer's disease
4. A controlled trial of tacrine in Alzheimer's disease
5. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease
6. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
7. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer's disease
8. Quantitative EEG during a double-blind trial of THA and Lecitin in patients with Alzheimer's disease
9. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease
10. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease
11. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
12. Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral, blood flow, glucose metabolism, EEG, and cognitive abilities
13. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG
14. Long-term treatment with tacrine (THA) in Alzheimer's disease - Evaluation of neuropsychological data
15. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial
16. Long-term tacrine (Cognex) treatment: Effect on nursing home placement and mortality
17. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
18. Apolipoprotein E genotype allele e4 and response to tacrine in Alzheimer's disease
19. Apolipoprotein E allele as a predictor of cholinergic deficits and treatment in Alzheimer disease
20. The treatment of Alzheimer's disease with anticholinesterase drugs
21. Tetrahydroaminoacridine and Alzheimer's disease
22. Tacrine for Alzheimer's disease - Which patient, what dose?
23. Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report
24. Serum levels of tacrine in relation to clinical response in Alzheimer's disease
25. Pretreatment postural blood pressure drop as possible predictor of response to the cholinesterase inhibitor Velnacrine (HP 029) in Alzheimer's disease
26. The presence of leuko-araiosis in patients with Alzheimer's disease predicts poor tolerance of tacrine, but does not discriminate responders from non-responders
27. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease
28. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease
29. The cholinergic hypothesis of geriatric memory dysfunction
30. Alzheimer's disease, attention, and the cholinergic system
31. AMPA-induced exitotoxic lesions of the basal fore-brain: A significant role of the cortical cholinergic system in attention function
32. Nicotinic systems and Alzheimer's disease: Implications for therapeutics
33. Basal forebrain lesions in monkeys disrupt attention but not learning and memory
34. Cholinergic control of cognitive resources
35. Clinical diagnosis of Alzheimer's disease
36. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician
37. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients
38. Episodic memory functioning in a community-based sample of very old adults with major depression: Utilization of cognitive support
39. SPES: A psychological test system to diagnose environmental hazards
40. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data
41. Determination of tacrine and the 1-hydroxy metabolite in plasma using HLPC
42. A new and rapid colorimetric determination of acetylcholinesterase activity
43. The cholinergic hypothesis of Alzheimer's disease: A review of progress
44. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease
45. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease
46. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes
47. Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors
48. 2 nAChRs in M10 cells
49. A review of its pharmacodynamic and pharmakokinetic properties, and therapeutic potential in Alzheimer disease
50. Cholinergic activity and constraints on information processing
51. Differential responsitivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations
52. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior
53. Patterns of memory failure after scopolamine treatment: Implications for the cholinergic hypothesis of dementia
54. Cholinergic control of cognitive resources
55. Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type
56. Attentional functions of the forebrain cholinergic systems: Effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task
57. Nicotinic potentionation of glutaminergic synapses in the prefrontal cortex: New insight into the analysis of the role of nicotinic receptors in cognitive functions
58. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease
59. Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging
60. A multi-center double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease
61. Physostigmine and Alzheimer's disease
62. Apolipoprotein E ε4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence
63. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differering apolipoprotein E genotype
64. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients
65. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease
66. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors